

Cerecin forges strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders.

Cerecin and IMCB signed a Memorandum of Understanding to collaborate in the areas of neurometabolism, neurodegeneration, metabolic regulators, and brain health and function.

Denver, Colorado, and Singapore – 30th November 2023 – Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding (MOU) with A*STAR's Institute of Molecular and Cell Biology (IMCB). This collaboration aims to accelerate research and treatment initiatives for neurological disorders and diseases to enhance overall health and brain function.

Worldwide, there are about two billion cases of neurological and mental health diseases. Unlike other therapeutic areas, 80% of these patients are completely unserved or have been inadequately served by current medicines with which to treat their conditions. This makes brain health one of the medical fields with the highest unmet need. In Singapore alone, more than one in four will suffer from a neurological condition within their lifetime.

It is becoming increasingly clear that neurometabolic dysfunction is a driver of many neurological and neurodegenerative diseases, and that metabolic and brain health are closely intertwined. Hence, in their collaboration, A*STAR's IMCB will combine preclinical modelling tools with multi-omics approaches to analyse bio samples in neurological diseases (such as Alzheimer's disease) from Cerecin's clinical cohorts. The goal is to understand the fundamental causes of these neurological diseases, especially their metabolic origins, to identify new treatment targets and disease indicators, and to develop innovative treatment approaches.

"We are very pleased to embark on this collaborative journey with A*STAR's IMCB, focused initially on working with its Neurometabolism division" said Dr Charles Stacey, CEO and President of Cerecin. "This partnership represents a further step in our commitment to driving advances in neurometabolism and underscores our dedication to providing cutting-edge solutions. Singapore has a rapidly ageing population. As age is the leading risk factor for many neurodegenerative diseases, we are proud to form one of the first public-private collaborations in brain health."



Dr Su Xinyi, Acting Executive Director at A*STAR's IMCB said, "Public-private partnerships are key enablers in translating science into impact. IMCB's expertise in neurometabolism, cell biology,

transformational biotherapeutics and diagnostics, coupled with Cerecin's expertise, will help pave the way for innovative developments in neurotherapeutics and contribute to better health outcomes for Singapore and beyond."

About Cerecin:

Cerecin is a clinical-stage biotechnology company focused on developing drugs that target the metabolic bases of central nervous system diseases. Cerecin is supported by two multinational partners, Nestlé S.A. (NSRGY) and Wilmar International Limited (SGX: F34), as well as a syndicate of leading institutional investors. By bringing together the deep expertise of its leadership team, Cerecin is becoming a global leader in bioenergetics and neurometabolism.

Forward looking statements:

This press release contains "forward-looking statements" under applicable securities laws that are based on the current expectations and beliefs of Cerecin. Such statements may be accompanied by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "possible," "will" and other words and terms of similar meaning. All statements, except for statements of historical fact, are statements that could be deemed forward-looking statements, including but not limited to: (i) sources and availability of third party financing and investments and the projected financial performance of the Company; (ii) the expected development of the Company's business, projects, drug development programs and joint ventures; (iii) execution of the Company's vision and growth strategy, including with respect to future growth; and (iv) new developments with respect to the Company's projects that are currently underway, in development or otherwise under consideration. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Forward-looking statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from projections of future performance or any result that may be expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management of Cerecin believes are reasonable assumptions, there can be no assurance or guarantee that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Cerecin undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

For more information visit www.cerecin.com.

For further information, please contact: pr@cerecin.com